Application of Bergstrom
Decision Date | 16 July 1970 |
Docket Number | Patent Appeal No. 8256. |
Citation | 427 F.2d 1394 |
Parties | Application of Sune BERGSTROM and Jan Sjovall. |
Court | U.S. Court of Customs and Patent Appeals (CCPA) |
Earl C. Spaeth, Kalamazoo, Mich., attorney of record, for appellants. Eugene O. Retter, George T. Johannesen, Kalamazoo, Mich., Sidney W. Russell, Arlington, Va., of counsel.
Joseph Schimmel, Washington, D. C., for the Commissioner of Patents. Fred W. Sherling, Washington, D. C., of counsel.
Before RICH, ALMOND, BALDWIN and LANE, Judges, and McMANUS, Chief Judge, Northern District of Iowa, sitting by designation.
This appeal is from the decision of the Patent Office Board of Appeals affirming the examiner's rejection of claims 23 and 53 in appellants' application1 for "PGE Type Compounds" "as lacking in novelty under 35 U.S.C. 101."
The invention relates to two chemical compounds, as reflected in the claims:
Both compounds, termed PGE2 and PGE3, respectively, are members of a family of compounds known collectively as prostaglandins. According to the specification, both are useful in stimulating smooth muscle and in lowering blood pressure.
Some background information will be helpful in understanding the issues raised by the decisions below.
In the late 1950's, appellants Bergstrom and Sjovall isolated two distinct chemical compounds in essentially pure crystalline form "from crude materials, such as von Euler prostaglandin, or directly from accessory genital materials such as prostate glands and sperm." Their discovery of those compounds, which were originally known as PGE and PGF (now PGE1 and PGF1) is described in their earlier application serial No. 738,514, now patent No. 3,069,322, issued Dec. 18, 1962, and the two pure compounds form the subject matter of some of the claims of that patent. Both compounds were found to have a smooth muscle stimulating effect, but only PGE has hypotensive activity. As described in similar language both in the patent and in the present application:
These compounds PGE1 and PGF1 are associated in the source materials and in crude extracts thereof with antigens and pyrogens, for example, tissue fragments, lipids, cellular debris, foreign proteins, and the like, and are not useful for parenteral applications. The isolation of these compounds free of antigens and pyrogens made it possible to utilize their pharmacodynamic effects without undesirable side effects or reactions.2
To isolate PGE1 and PGF1, it appears from the Bergstrom et al. patent and the present application that appellants first prepared a crude extract containing PGE1 and PGF1 by subjecting sheep prostate gland to alternate alcohol, ether and alkaline phosphate buffer extractions somewhat in the manner of von Euler. A solid residue obtained upon drying a final ether extraction was then given a preliminary purification by subjecting it to a "five stage countercurrent distribution" between ether and phosphate buffer, and the resultant ether and buffer phases were dried. Certain of the dried ether and buffer phases were then pooled and subjected to two different "reversed phase partition chromatography" procedures employing two different solvent systems. Certain fractions of the eluate obtained from that purification procedure yielded crystals of essentially pure PGE1 and PGF1.
In 1960, appellants also published a description of their work relating to the isolation of PGE1 and PGF1 in Acta Chemica Scandinavica, 14, 1693-1705 (1960). The procedure with respect to the isolation of PGE1 was described thus:
In Examples 4 and 5 of the present application, appellants describe a procedure for separate isolation of PGE2 and PGE3 in addition to PGE1 which closely resembles the process described in their 1960 publication up to the point where the second reversed-phase chromatography run was begun. Thereupon, appellants changed their procedure and subjected the pooled effluent fractions from the first chromatography run to a different chromatographic process. They obtained three separate fractions having physiological activity from which pure PGE1, PGE2, and PGE3 were individually isolated.
Faced with that set of facts, the examiner rejected claims 23 and 53 under § 101. Inasmuch as the "claimed compounds are naturally occurring," said the examiner, they therefore "are not `new' within the connotation of the patent statute," citing Ex parte Snell, 86 USPQ 496 (1950). In support of her rejection, and in contrast to appellants' contention that both claims are directed not to naturally occurring materials but to pure compounds which do not exist in pure form in nature, the examiner noted that she could not "determine from the claims exactly what is included or excluded." She thought the language of both claims sufficiently broad to embrace and not distinguish from either (1) the mother liquors which apparently inherently contain PGE2 and PGE3 and from which PGE1 is crystallized, as described in the 1960 Bergstrom et al. publication, or (2) those compounds as they inherently occur in previously known crude extracts or even in nature. In view of that, and because...
To continue reading
Request your trial-
Scripps Clinic & Research Foundation v. Genentech, Inc., Nos. 89-1541
...court. While judicial attention has on occasion focused on the patentability of claims in this context, see, e.g., In re Bergstrom, 427 F.2d 1394, 166 USPQ 256 (CCPA 1970), Genentech, by conceding that the product claims were appropriately granted, presents inconsistent legal arguments. Gen......
-
Application of Bergy
...has disclosed only two instances in which rejections for lack of novelty were made by the PTO under § 101, In re Bergstrom, 427 F.2d 1394, 57 CCPA 1240, 166 USPQ 256 (1970); In re Seaborg, 328 F.2d 996, 51 CCPA 1109, 140 USPQ 662 (1964). In In re Bergstrom we in effect treated the rejection......
-
Ass'n For Molecular Pathology v. United States Patent
...that ‘do not exist in nature in pure form’ renders such compounds patent-eligible.” Myriad Br. at 21 (quoting In re Bergstrom, 57 C.C.P.A. 1240, 427 F.2d 1394, 1401 (1970)). However, Myriad cites no Supreme Court authority that would rebut the authorities presented by Plaintiffs, nor do the......
-
Nickola v. Peterson
...appear in H.R.Rep.No.1923, 82nd Cong., 2d Sess. (1952) at pp. 6, 7, and 17, respectively. As stated in In re Bergstrom, 427 F.2d 1394, 1401, 57 CCPA 1240, 1249, 166 USPQ 256, 262 (1970): "(T)he criteria for determining whether given subject matter is 'new' within the meaning of § 101 are no......
-
Navigating The Isolated DNA Patent Eligibility Jungle
...a chemical that gives strawberries their flavor in In re Kratz 592 F.2d 1169, (C.C.P.A 1979); Purified prostaglandin in In re Bergstrom 427 F.2d 1394 (C.C.P.A 1970); Purified Factor VIII in Scripps v. Genentech 666 F. Supp. 1379 (N.D. Cal. 1987); But See patentability of ductile vanadium In......